Biology Reference
In-Depth Information
29. Olea FD, Vera Janavel G, De Lorenzi A,
Cuniberti L, Yannarelli G, Cabeza Meckert P,
Cearras M, Laguens R, Crottogini A (2006)
High-dose erythropoietin has no long-term
protective effects in sheep with reperfused
myocardial infarction. J Cardiovasc Pharmacol
47:736-741
30. Liu X, Zhou Z, Feng X, Jia Z, Jin Y, Xu J
(2006) Cyclooxygenase-2 plays an essential
part in cardioprotection of delayed phase of
recombinant human erythropoietin precondi-
tioning in rats. Postgrad Med J 82:588-593
31. Gao E, Boucher M, Chuprun JK, Zhou RH,
Eckhart AD, Koch WJ (2007) Darbepoetin
alfa, a long-acting erythropoietin analog, offers
novel and delayed cardioprotection for the
ischemic heart. Am J Physiol Heart Circ
Physiol 293:H60-H68
32. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell
JS, Gross GJ (2007) Darbepoetin-alfa protects
the rat heart against infarction: dose-response,
phase of action, and mechanisms. J Cardiovasc
Pharmacol 49:337-345
33. Toma C, Letts DP, Tanabe M, Gorcsan J III,
Counihan PJ (2007) Positive effect of darbe-
poetin on peri-infarction remodeling in a por-
cine model of myocardial ischemia-reperfusion.
J Mol Cell Cardiol 43:130-136
34. Singh D, Kolarova JD, Wang S, Ayoub IM,
Gazmuri RJ (2007) Myocardial protection by
erythropoietin during resuscitation from ven-
tricular fibrillation. Am J Ther 14:361-368
35. Boucher M, Pesant S, Lei YH, Nanton N,
Most P, Eckhart AD, Koch WJ, Gao E (2008)
Simultaneous administration of insulin-like
growth factor-1 and darbepoetin-alfa protects
the rat myocardium against myocardial infarc-
tion and enhances angiogenesis. Clin Transl
Sci 1:13-20
36. Prunier F, Pottier P, Clairand R, Mercier A,
Hajjar RJ, Planchon B, Furber A (2009)
Chronic erythropoietin treatment decreases
post-infarct myocardial damage in rats without
venous thrombogenic effect. Cardiology
112:129-134
37. Shan X, Xu X, Cao B, Wang Y, Guo L, Zhu Q,
Li J, Que L, Chen Q, Ha T, Li C, Li Y (2009)
Transcription factor GATA-4 is involved in
erythropoietin-induced cardioprotection
against myocardial ischemia/reperfusion
injury. Int J Cardiol 134:384-392
38. Doue T, Ohtsuki K, Ogawa K, Ueda M,
Azuma A, Saji H, Strauss HW, Matsubara H
(2008) Cardioprotective effects of erythropoi-
etin in rats subjected to ischemia-reperfusion
injury: assessment of infarct size with 99mTc-
annexin V. J Nucl Med 49:1694-1700
39. Huang CH, Hsu CY, Tsai MS, Wang TD,
Chang WT, Chen WJ (2008) Cardioprotective
effects of erythropoietin on post-resuscita-
tion myocardial dysfunction in appropriate
therapeutic windows. Crit Care Med 36:
S467-S473
40. Burger D, Xiang F, Hammoud L, Lu X, Feng
Q (2009) Role of heme oxygenase-1 in the
cardioprotective effects of erythropoietin dur-
ing myocardial ischemia and reperfusion. Am J
Physiol Heart Circ Physiol 296:H84-H93
41. Burger DE, Xiang FL, Hammoud L, Jones
DL, Feng Q (2009) Erythropoietin protects
the heart from ventricular arrhythmia during
ischemia and reperfusion via neuronal nitric-
oxide synthase. J Pharmacol Exp Ther
329:900-907
42. French CJ, Zaman AK, Sobel BE (2009)
Failure of erythropoietin to render jeopardized
ischemic myocardium amenable to incremen-
tal salvage by early reperfusion. Coron Artery
Dis 20:295-299
43. Schlecht-Bauer D, Antier D, Machet MC,
Hyvelin JM (2009) Short- and long-term car-
dioprotective effect of darbepoetin-alpha: role
of Bcl-2 family proteins. J Cardiovasc
Pharmacol 54:223-231
44. Tamareille S, Ghaboura N, Treguer F,
Khachman D, Croué A, Henrion D, Furber A,
Prunier F (2009) Myocardial reperfusion
injury management: erythropoietin compared
with postconditioning. Am J Physiol Heart
Circ Physiol 297:H2035-H2043
45. Miki T, Miura T, Hotta H, Tanno M, Yano T,
Sato T, Terashima Y, Takada A, Ishikawa S,
Shimamoto K (2009) Endoplasmic reticulum
stress in diabetic hearts abolishes erythropoie-
tin-induced myocardial protection by impair-
ment of phospho-glycogen synthase
kinase-3beta-mediated suppression of mito-
chondrial permeability transition. Diabetes
58:2863-2872
46. Hotta H, Miura T, Miki T, Togashi N, Maeda
T, Kim SJ, Tanno M, Yano T, Kuno A, Itoh T,
Satoh T, Terashima Y, Ishikawa S, Shimamoto
K (2010) Angiotensin II type 1 receptor-
mediated upregulation of calcineurin activity
underlies impairment of cardioprotective signal-
ing in diabetic hearts. Circ Res 106:129-132
47. Treguer F, Donal E, Tamareille S, Ghaboura
N, Derumeaux G, Furber A, Prunier F (2010)
Speckle tracking imaging improves in vivo
assessment of EPO-induced myocardial salvage
early after ischemia-reperfusion in rats. Am J
Physiol
Heart
Circ
Physiol
298:H1679-H1686
48. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong
G, Huang H, Jing H (2010) Recombinant
human erythropoietin pretreatment attenuates
heart ischemia-reperfusion injury in rats by
suppressing the systemic inflammatory
response. Transplant Proc 42:1595-1597
49. Stein A, Knödler M, Makowski M, Kühnel S,
Nekolla S, Keithahn A, Weidl E, Groha P,
Schürmann M, Saraste A, Botnar R,
Search WWH ::
Custom Search